GSA Capital Partners’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $461K | Sell |
265,075
-194,753
| -42% | -$321K | 0.03% | 969 |
|
|
2025
Q4 | $800K | Buy |
459,828
+16,724
| +4% | +$36.8K | 0.07% | 489 |
|
|
2025
Q3 | $1.04M | Buy |
443,104
+279,844
| +171% | +$536K | 0.09% | 375 |
|
|
2025
Q2 | $332K | Buy |
+163,260
| New | +$313K | 0.02% | 1195 |
|
|
2024
Q2 | – | Sell |
-79,979
| Closed | -$1.11M | – | 1820 |
|
|
2024
Q1 | $1.11M | Sell |
79,979
-236,398
| -75% | -$2.04M | 0.09% | 372 |
|
|
2023
Q4 | $1.94M | Buy |
316,377
+291,631
| +1,178% | +$1.44M | 0.16% | 129 |
|
|
2023
Q3 | $116K | Buy |
+24,746
| New | +$137K | 0.01% | 1371 |
|
|
2023
Q2 | – | Sell |
-8,356
| Closed | -$82K | – | 1711 |
|
|
2023
Q1 | $82K | Sell |
8,356
-4,984
| -37% | -$85K | 0.01% | 1377 |
|
|
2022
Q4 | $250K | Buy |
+13,340
| New | +$302K | 0.03% | 1050 |
|
|
2022
Q3 | – | Sell |
-3,230
| Closed | -$67K | – | 1689 |
|
|
2022
Q2 | $67K | Sell |
3,230
-4,857
| -60% | -$137K | 0.01% | 1263 |
|
|
2022
Q1 | $348K | Buy |
8,087
+3,507
| +77% | +$158K | 0.05% | 792 |
|
|
2021
Q4 | $274K | Buy |
4,580
+1,755
| +62% | +$141K | 0.03% | 1000 |
|
|
2021
Q3 | $243K | Buy |
2,825
+849
| +43% | +$85.2K | 0.02% | 1137 |
|
|
2021
Q2 | $220K | Sell |
1,976
-71
| -3% | -$6.82K | 0.02% | 1135 |
|
|
2021
Q1 | $228K | Buy |
2,047
+473
| +30% | +$62.2K | 0.04% | 817 |
|
|
2020
Q4 | $167K | Buy |
+1,574
| New | +$210K | 0.03% | 1030 |
|
|
2020
Q2 | – | Sell |
-2,288
| Closed | -$204K | – | 850 |
|
|
2020
Q1 | $204K | Buy |
+2,288
| New | +$141K | 0.05% | 749 |
|
|
2017
Q4 | – | Sell |
-9,608
| Closed | -$731K | – | 1672 |
|
|
2017
Q3 | $731K | Sell |
9,608
-1,392
| -13% | -$104K | 0.05% | 713 |
|
|
2017
Q2 | $1.03M | Buy |
+11,000
| New | +$941K | 0.07% | 521 |
|
|
2016
Q4 | – | Sell |
-7,867
| Closed | -$880K | – | 1852 |
|
|
2016
Q3 | $880K | Buy |
7,867
+2,100
| +36% | +$232K | 0.05% | 688 |
|
|
2016
Q2 | $639K | Buy |
5,767
+3,650
| +172% | +$443K | 0.04% | 937 |
|
|
2016
Q1 | $221K | Sell |
2,117
-866
| -29% | -$66.9K | 0.01% | 1450 |
|
|
2015
Q4 | $241K | Buy |
+2,983
| New | +$237K | 0.01% | 1572 |
|
|
2015
Q3 | – | Sell |
-7,183
| Closed | -$703K | – | 1875 |
|
|
2015
Q2 | $703K | Buy |
7,183
+4,241
| +144% | +$453K | 0.03% | 1143 |
|
|
2015
Q1 | $288K | Buy |
+2,942
| New | +$285K | 0.01% | 1732 |
|
|
2014
Q4 | – | Sell |
-1,283
| Closed | -$152K | – | 1798 |
|
|
2014
Q3 | $152K | Buy |
+1,283
| New | +$160K | 0.01% | 1574 |
|
Other funds holding INO
VCM
BCM
ACM
EP
GSA Capital Partners's INO Position: Q1 2026 in Review
GSA Capital Partners reduced its Inovio Pharmaceuticals (INO) stake by 42% in Q1 2026, selling an estimated $321K and leaving 265,075 shares worth $461K. The position accounts for 0.03% of the portfolio, ranked #969.
GSA Capital Partners first reported a position in INO in Q3 2014 and has held it in 26 quarters since. The position peaked at $1.94M in Q4 2023. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.
- GSA Capital Partners held 265,075 shares of Inovio Pharmaceuticals worth $461K as of Q1 2026.
- GSA Capital Partners sold 194,753 Inovio Pharmaceuticals shares in Q1 2026, an estimated $321K.
- Inovio Pharmaceuticals made up 0.03% of GSA Capital Partners's portfolio in Q1 2026, its #969 holding.
- GSA Capital Partners first reported a position in Inovio Pharmaceuticals in Q3 2014 and has held it in 26 quarters since.
- GSA Capital Partners's Inovio Pharmaceuticals position peaked at $1.94M in Q4 2023.
- 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.
Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.